Brief: Aeon Biopharma Presents Positive Results From Phase 2 Clinical Trial Of Abp-450 In Cervical Dystonia
29/08/2023 13:05
Aug 29 (Reuters) - Aeon Biopharma Inc AEON.A :
* AEON BIOPHARMA PRESENTS POSITIVE RESULTS FROM PHASE 2
CLINICAL
TRIAL OF ABP-450 (PRABOTULINUMTOXINA) IN CERVICAL DYSTONIA AT
THE INTERNATIONAL PARKINSON AND MOVEMENT DISORDERS SOCIETY
CONGRESS®
* AEON BIOPHARMA INC - ON TRACK TO ANNOUNCE TOPLINE DATA
FROM OUR
ONGOING PHASE 2 STUDY OF ABP-450 IN EPISODIC MIGRAINE IN FALL OF
2023
* AEON BIOPHARMA: IN DISCUSSIONS WITH FDA FOR DESIGN OF
PHASE 3
STUDY IN CD, WHICH WE EXPECT TO START IN 2024 BASED ON
AVAILABILITY OF CAPITAL RESOURCES
Source text for Eikon: ID:nGNX6j5dbl
Further company coverage: AEON.A
Recent news on Aeon Biopharma
See all newsBrief: Aeon Biopharma Reports bpd Type 2A Meeting With FDA And Shareholder Approval Of The November Transactions
Brief: Aeon Biopharma Announces Execution Of Exchange Agreement With Daewoong
Brief: Aeon Biopharma Announces First Closing Of Pipe Investment And Provides Update On FDA Type 2A Meeting Scheduling
Brief: Aeon Biopharma Announces FDA bpd Type 2A Meeting For Abp-450 On November 19
Brief: Aeon Biopharma Announces CEO Transition